Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis

This open‐label disease‐drug–drug interaction study assessed whether blockade of the interleukin (IL)‐17A pathway by secukinumab and subsequent downregulation of inflammatory cytokines like IL‐6 or high‐sensitivity C‐reactive protein affects the pharmacokinetics (PKs) of a sensitive probe substrate...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Pharmacol Ther
Asıl Yazarlar: Bruin, Gerard, Hasselberg, Anke, Koroleva, Irina, Milojevic, Julie, Calonder, Claudio, Soon, Rachel, Woessner, Ralph, Pariser, David M., Boutouyrie‐Dumont, Bruno
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896234/
https://ncbi.nlm.nih.gov/pubmed/31228872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1558
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller